Compare Stocks: KOD, BNTX, INSM, and EXEL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$91.31 +0.0%	$98.85	$79.52 ▼ $124.00	$23.04B	1.25	1.09 million shs	185,552 shs
EXEL Exelixis	$64.74 +0.3%	$57.63	$36.00 ▼ $65.20	$16.04B	0.47	2.59 million shs	244,103 shs
INSM Insmed	$94.39 +0.4%	$116.48	$90.39 ▼ $212.75	$20.55B	0.83	2.91 million shs	475,406 shs
KOD Kodiak Sciences	$87.25 -0.5%	$56.27	$15.83 ▼ $104.00	$5.47B	2.03	1.14 million shs	132,150 shs

10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	+0.13%	+2.97%	-6.85%	-0.84%	-14.59%
EXEL Exelixis	+0.30%	+5.89%	+12.86%	+16.05%	+78.74%
INSM Insmed	-1.70%	-3.83%	-22.28%	-12.45%	-43.11%
KOD Kodiak Sciences	-5.65%	+8.18%	+170.57%	+113.85%	+361.68%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$91.31 +0.0%	$98.85	$79.52 ▼ $124.00	$23.04B	1.25	1.09 million shs	185,552 shs
EXEL Exelixis	$64.74 +0.3%	$57.63	$36.00 ▼ $65.20	$16.04B	0.47	2.59 million shs	244,103 shs
INSM Insmed	$94.39 +0.4%	$116.48	$90.39 ▼ $212.75	$20.55B	0.83	2.91 million shs	475,406 shs
KOD Kodiak Sciences	$87.25 -0.5%	$56.27	$15.83 ▼ $104.00	$5.47B	2.03	1.14 million shs	132,150 shs

10 Best Stocks to Own in Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	+0.13%	+2.97%	-6.85%	-0.84%	-14.59%
EXEL Exelixis	+0.30%	+5.89%	+12.86%	+16.05%	+78.74%
INSM Insmed	-1.70%	-3.83%	-22.28%	-12.45%	-43.11%
KOD Kodiak Sciences	-5.65%	+8.18%	+170.57%	+113.85%	+361.68%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTX BioNTech	2.65	Moderate Buy	$125.44	37.38% Upside
EXEL Exelixis	2.35	Hold	$51.50	-20.45% Downside
INSM Insmed	2.92	Moderate Buy	$198.91	110.73% Upside
KOD Kodiak Sciences	2.63	Moderate Buy	$104.71	20.02% Upside

Current Analyst Ratings Breakdown

Latest KOD, BNTX, INSM, and EXEL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/21/2026	INSM Insmed	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$218.00 ➝ $213.00
10/20/2026	INSM Insmed	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$173.00
10/19/2026	EXEL Exelixis	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform
10/19/2026	EXEL Exelixis	Citizens Jmp Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Market Outperform	$55.00 ➝ $65.00
10/15/2026	INSM Insmed	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/14/2026	BNTX BioNTech	Canaccord Genuity Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$136.00 ➝ $132.00
10/12/2026	INSM Insmed	Bank of America Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$207.00
10/12/2026	INSM Insmed	Wolfe Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Outperform ➝ Peer Perform
10/12/2026	INSM Insmed	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$220.00
10/12/2026	KOD Kodiak Sciences	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$96.00 ➝ $126.00
10/9/2026	EXEL Exelixis	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Sector Perform	$45.00 ➝ $51.00

(Data available from 10/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTX BioNTech	$3.25B	7.11	$1.34 per share	68.29	$96.59 per share	0.95
EXEL Exelixis	$2.32B	6.91	$3.04 per share	21.27	$8.06 per share	8.03
INSM Insmed	$1.14B	18.12	N/A	N/A	$3.46 per share	27.28
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	$2.97 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTX BioNTech	-$1.29B	-$7.83	N/A	N/A	N/A	-63.54%	-6.86%	-6.00%	11/3/2026 (Estimated)
EXEL Exelixis	$782.57M	$3.18	20.35	17.45	1.81	35.33%	42.17%	31.76%	10/29/2026 (Estimated)
INSM Insmed	-$1.28B	-$4.11	N/A	93.46	N/A	-76.94%	-123.94%	-44.30%	10/29/2026 (Estimated)
KOD Kodiak Sciences	-$229.97M	-$4.19	N/A	N/A	N/A	N/A	-273.23%	-85.48%	11/12/2026 (Estimated)

Latest KOD, BNTX, INSM, and EXEL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/12/2026	Q3 2026	KOD Kodiak Sciences	-$1.06	N/A	N/A	N/A	N/A	N/A
11/3/2026	Q3 2026	BNTX BioNTech	$0.8490	N/A	N/A	N/A	$1.19 billion	N/A
10/29/2026	Q3 2026	EXEL Exelixis	$0.8790	N/A	N/A	N/A	$646.52 million	N/A
10/29/2026	Q3 2026	INSM Insmed	-$0.3879	N/A	N/A	N/A	$499.06 million	N/A
8/13/2026	Q2 2026	KOD Kodiak Sciences	-$0.9565	-$1.05	-$0.0935	-$1.05	N/A	N/A
8/6/2026	Q2 2026	INSM Insmed	-$0.6724	-$0.06	+$0.6124	-$0.06	$395.50 million	$425.49 million
8/5/2026	Q2 2026	EXEL Exelixis	$0.8530	$0.91	+$0.0570	$0.8438	$636.40 million	$628.69 million
8/4/2026	Q2 2026	BNTX BioNTech	-$2.3983	-$2.5340	-$0.1357	-$3.70	$180.18 million	$122.31 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTX BioNTech	N/A	N/A	N/A	N/A	N/A
EXEL Exelixis	N/A	N/A	N/A	N/A	N/A
INSM Insmed	N/A	N/A	N/A	N/A	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTX BioNTech	0.01	7.85	7.80
EXEL Exelixis	N/A	3.46	3.38
INSM Insmed	0.74	3.72	3.40
KOD Kodiak Sciences	N/A	2.49	2.49

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTX BioNTech	15.52%
EXEL Exelixis	85.27%
INSM Insmed	N/A
KOD Kodiak Sciences	89.06%

Insider Ownership

Company	Insider Ownership
BNTX BioNTech	19.20%
EXEL Exelixis	2.60%
INSM Insmed	2.10%
KOD Kodiak Sciences	44.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTX BioNTech	7,807	252.88 million	204.33 million	Optionable
EXEL Exelixis	1,077	247.78 million	241.34 million	Optionable
INSM Insmed	1,664	218.38 million	213.80 million	Optionable
KOD Kodiak Sciences	124	62.85 million	34.94 million	Optionable

KOD, BNTX, INSM, and EXEL Headlines

Recent News About These Companies

Kodiak Sciences (NASDAQ:KOD) Shares Down 5.7% - Should You Sell?

October 21 at 3:39 PM | marketbeat.com

Kodiak Sciences (NASDAQ:KOD) Stock Price Up 6.5% - Here's Why

October 19 at 2:39 PM | marketbeat.com

Can Zenkuda's Multi-Indication Potential Drive KOD Stock Higher?

October 19 at 10:11 AM | zacks.com

H.C. Wainwright raises Kodiak Sciences stock target to USD 126.00

October 18, 2026 | ad-hoc-news.deA

Kodiak Sciences Inc. (KOD) - What Are Investment Firms Saying About This Stock?

October 18, 2026 | americanbankingnews.com

HC Wainwright Expects Increased Earnings for Kodiak Sciences

October 16, 2026 | americanbankingnews.com

HC Wainwright Comments on Kodiak Sciences FY2030 Earnings

October 15, 2026 | americanbankingnews.com

FY2028 EPS Estimate for Kodiak Sciences Boosted by Analyst

October 14, 2026 | marketbeat.com

Kodiak Sciences (NASDAQ:KOD) Stock Price Down 7.7% - What's Next?

October 13, 2026 | marketbeat.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Kodiak Sciences (KOD), Newron Pharmaceuticals SpA (OtherNWPHF) and Illumina (ILMN)

October 13, 2026 | theglobeandmail.com

HC Wainwright Expects Higher Earnings for Kodiak Sciences

October 13, 2026 | marketbeat.com

Kodiak Sciences Inc. (KOD) - What Are Researchers Thinking About This Stock?

October 13, 2026 | marketbeat.com

HC Wainwright Issues Positive Forecast for Kodiak Sciences (NASDAQ:KOD) Stock Price

October 12, 2026 | marketbeat.com

Kodiak Sciences Inc. (KOD) Presents at American Academy of Ophthalmology Conference 2026 - Slideshow

October 10, 2026 | seekingalpha.com

Kodiak Sciences (KOD) Stock Trades At A Premium On DAYBREAK Trial News

October 9, 2026 | finance.yahoo.com

Kodiak Sciences (KOD) Could Be 7% Overvalued Following Late Stage Data Update

October 8, 2026 | finance.yahoo.com

Kodiak Sciences stock heads into AAO data on October 9

October 8, 2026 | ad-hoc-news.deA

Wall Street Zen upgrades Kodiak Sciences stock to Sell

October 8, 2026 | ad-hoc-news.deA

Kodiak Sciences Inc. Presents Clinical Data Across All Three Late-Stage Programs At AAO 2026

October 7, 2026 | marketscreener.comM

Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026

October 7, 2026 | prnewswire.com

Kodiak Sciences stock gets closer to a BLA after DAYBREAK data

October 5, 2026 | ad-hoc-news.deA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

KOD, BNTX, INSM, and EXEL Company Descriptions

BioNTech NASDAQ:BNTX

$91.30 +0.02 (+0.02%)

As of 10:43 AM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Exelixis NASDAQ:EXEL

$64.74 +0.16 (+0.25%)

As of 10:44 AM Eastern

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Insmed NASDAQ:INSM

$94.39 +0.35 (+0.38%)

As of 10:44 AM Eastern

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Kodiak Sciences NASDAQ:KOD

$87.24 -0.48 (-0.54%)

As of 10:44 AM Eastern

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KOD, BNTX, INSM, and EXEL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KOD, BNTX, INSM, and EXEL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KOD, BNTX, INSM, and EXEL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

KOD, BNTX, INSM, and EXEL Company Descriptions

BioNTech NASDAQ:BNTX

Exelixis NASDAQ:EXEL

Insmed NASDAQ:INSM

Kodiak Sciences NASDAQ:KOD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KOD, BNTX, INSM, and EXEL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KOD, BNTX, INSM, and EXEL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KOD, BNTX, INSM, and EXEL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

KOD, BNTX, INSM, and EXEL Company Descriptions

BioNTech NASDAQ:BNTX

Exelixis NASDAQ:EXEL

Insmed NASDAQ:INSM

Kodiak Sciences NASDAQ:KOD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools